B
B.M. Zonderhuis
Researcher at VU University Amsterdam
Publications - 44
Citations - 758
B.M. Zonderhuis is an academic researcher from VU University Amsterdam. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 12, co-authored 25 publications receiving 454 citations. Previous affiliations of B.M. Zonderhuis include VU University Medical Center & University of Amsterdam.
Papers
More filters
Journal ArticleDOI
A comparison of three methods for nonpalpable breast cancer excision
N.M.A. Krekel,B.M. Zonderhuis,Hein B.A.C. Stockmann,W. H. (Hermien) Schreurs,H. van der Veen,E. S. M. de Lange-de Klerk,Sybren L. Meijer,M.P. van den Tol +7 more
TL;DR: US-guided BCS for nonpalpable invasive breast cancer was more accurate than WL- and ROLL-guided surgery because it optimised the surgeon's ability to obtain adequate margins.
Journal ArticleDOI
Percutaneous Irreversible Electroporation in Locally Advanced and Recurrent Pancreatic Cancer (PANFIRE-2): A Multicenter, Prospective, Single-Arm, Phase II Study.
Alette H. Ruarus,Laurien G. P. H. Vroomen,Bart Geboers,Eran van Veldhuisen,Robbert S. Puijk,Sanne Nieuwenhuizen,Marc G. Besselink,B.M. Zonderhuis,Geert Kazemier,Tanja D. de Gruijl,Krijn P. van Lienden,Jan J. J. de Vries,Hester J. Scheffer,Martijn R. Meijerink +13 more
TL;DR: The target median overall survival with CT-guided percutaneous irreversible electroporation was exceeded in participants with locally advanced pancreatic cancer and those with local recurrence (16 months); one of these deaths was likely related to IRE.
Journal ArticleDOI
Resectability and Ablatability Criteria for the Treatment of Liver Only Colorectal Metastases : Multidisciplinary Consensus Document from the COLLISION Trial Group
Sanne Nieuwenhuizen,Robbert S. Puijk,Bente van den Bemd,Luca Aldrighetti,Mark J. Arntz,Peter B. van den Boezem,A. Bruynzeel,Mark C. Burgmans,Francesco De Cobelli,Marielle M.E. Coolsen,Cornelis H. C. Dejong,Sarah Derks,Arjen Diederik,Peter van Duijvendijk,Hasan H. Eker,Anton F. Engelsman,Joris I. Erdmann,Jurgen J. Fütterer,Bart Geboers,Gerie Groot,C.J.A. Haasbeek,Jan Jaap Janssen,Koert P. de Jong,G. Matthijs Kater,Geert Kazemier,Johan W.H. Kruimer,Wouter K. G. Leclercq,Christiaan van der Leij,Eric R. Manusama,Mark A.J. Meier,Bram B. van der Meijs,Marleen C. A. M. Melenhorst,Karin Nielsen,Maarten W Nijkamp,Fons H. Potters,Warner Prevoo,Floris J. Rietema,Alette H. Ruarus,Simeon J. S. Ruiter,Evelien A. C. Schouten,Gian Piero Serafino,Colin Sietses,Rutger-Jan Swijnenburg,Florentine E. F. Timmer,Kathelijn S. Versteeg,Ted Vink,Jan J. J. de Vries,Johannes H. W. de Wilt,B.M. Zonderhuis,Hester J. Scheffer,Petrousjka van den Tol,Martijn R. Meijerink +51 more
TL;DR: An interdisciplinary, consensus-based algorithm with specific resectability and ablatability criteria for the treatment of colorectal liver metastases (CRLM) is created to aid tumor board discussions, improve consistency when designing prospective trials and advance intersociety communications.
Journal ArticleDOI
Total neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2 trial): study protocol for a nationwide multicenter randomized controlled trial
Quisette P. Janssen,J.L. van Dam,Bert A. Bonsing,H. Bos,Koop Bosscha,P. P. L. O. Coene,C.H.J. van Eijck,I.H.J.T. de Hingh,Tom M. Karsten,M. van der Kolk,Gijs A. Patijn,M. Liem,H.C. van Santvoort,O. J. L. Loosveld,J. de Vos-Geelen,B.M. Zonderhuis,Marjolein Y.V. Homs,G. van Tienhoven,M.G. Besselink,Johanna W. Wilmink,B. Groot Koerkamp +20 more
TL;DR: The PREOPANC-2 trial as discussed by the authors investigated whether neoadjuvant FOLFIRINOX improves overall survival compared with single-agent chemotherapy regimens in patients with resectable and borderline-rescittable pancreatic cancer.
Journal ArticleDOI
Outcomes and Treatment Options for Duodenal Adenocarcinoma: A Systematic Review and Meta-Analysis.
Laura L. Meijer,Anna J Alberga,Jacob K de Bakker,Hans J. van der Vliet,Tessa Y S Le Large,Nicole C.T. van Grieken,Ralph de Vries,Freek Daams,B.M. Zonderhuis,Geert Kazemier +9 more
TL;DR: Resection with curative intent, either pancreaticoduodenectomy or segmental resection, and lack of nodal metastases, favors survival for DA, and no survival benefit for adjuvant therapy after curative resection was found.